Diaceutics PLC
Sembol: DIUXF
PNK
1.3672
USDBugünkü piyasa fiyatı
-124.8659
F/K Oranı
2.7906
PEG Oranı
123.70M
MRK Kapağı
- 0.00%
DIV Verimi
Diaceutics PLC (DIUXF) Finansal Tablolar
Bilanço
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 19.8 | 19.7 | 25.3 | |||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.net-receivables | 0 | 10.4 | 10 | 7.8 | |||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.other-current-assets | 0 | 0.6 | 0.4 | 0.6 | |||||||
balance-sheet.row.total-current-assets | 0 | 30.9 | 30.1 | 33.6 | |||||||
balance-sheet.row.property-plant-equipment-net | 0 | 2.1 | 2.1 | 0.2 | |||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 0 | 15.2 | 12.8 | 9.4 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 15.2 | 12.8 | 9.4 | |||||||
balance-sheet.row.long-term-investments | 0 | 17.1 | 14.7 | 9.2 | |||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0.3 | |||||||
balance-sheet.row.other-non-current-assets | 0 | -17.1 | -14.7 | -9.2 | |||||||
balance-sheet.row.total-non-current-assets | 0 | 17.4 | 15 | 9.9 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 0 | 48.3 | 45 | 43.5 | |||||||
balance-sheet.row.account-payables | 0 | 0.8 | 0.5 | 0.5 | |||||||
balance-sheet.row.short-term-debt | 0 | 0.1 | 0.3 | 0.1 | |||||||
balance-sheet.row.tax-payables | 0 | 0.4 | 0.3 | 0.8 | |||||||
balance-sheet.row.long-term-debt-total | 0 | 1.2 | 1.3 | 0 | |||||||
Deferred Revenue Non Current | 0 | 0 | -0.4 | 0 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 0 | 2.5 | 1.6 | 2 | |||||||
balance-sheet.row.total-non-current-liabilities | 0 | 2 | 1.7 | 0.4 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 0 | 1.3 | 1.4 | 0 | |||||||
balance-sheet.row.total-liab | 0 | 5.7 | 4.4 | 3.3 | |||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0.3 | 0 | |||||||
balance-sheet.row.common-stock | 0 | 0.2 | 0.2 | 0.2 | |||||||
balance-sheet.row.retained-earnings | 0 | 5.3 | 4.1 | 3.2 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0.1 | -0.3 | 0 | |||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 36.9 | 36.4 | 36.9 | |||||||
balance-sheet.row.total-stockholders-equity | 0 | 42.5 | 40.6 | 40.2 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 48.3 | 45 | 43.5 | |||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-equity | 0 | 42.5 | 40.6 | 40.2 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||
Total Investments | 0 | 17.1 | 14.7 | 9.2 | |||||||
balance-sheet.row.total-debt | 0 | 1.3 | 1.6 | 0.1 | |||||||
balance-sheet.row.net-debt | 0 | -18.5 | -18.1 | -25.1 |
Nakit Akış Tablosu
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 0.6 | 0.5 | -0.7 | |||||||
cash-flows.row.depreciation-and-amortization | 0 | 3 | 1.8 | 0.8 | |||||||
cash-flows.row.deferred-income-tax | 0 | 1.3 | -0.5 | -0.7 | |||||||
cash-flows.row.stock-based-compensation | 0 | 0.5 | 0.4 | 0.3 | |||||||
cash-flows.row.change-in-working-capital | 0 | -0.3 | -1.7 | 0.5 | |||||||
cash-flows.row.account-receivables | 0 | -1.6 | -1.5 | 0.5 | |||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.account-payables | 0 | 1.3 | -0.2 | -0.1 | |||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-non-cash-items | 0 | 0 | 0.1 | 0 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -4.9 | -5.6 | -6.3 | |||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-investing-activites | 0 | 0.1 | 0 | 0 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -4.8 | -5.6 | -6.3 | |||||||
cash-flows.row.debt-repayment | 0 | 0 | -0.1 | 0 | |||||||
cash-flows.row.common-stock-issued | 0 | 0.1 | 0 | 19.6 | |||||||
cash-flows.row.common-stock-repurchased | 0 | -0.1 | -0.2 | 0 | |||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-financing-activites | 0 | -0.2 | 0 | 0 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -0.2 | -0.3 | 19.6 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | -0.3 | 0 | |||||||
cash-flows.row.net-change-in-cash | 0 | 0.2 | -5.6 | 13.5 | |||||||
cash-flows.row.cash-at-end-of-period | 0 | 19.8 | 19.7 | 25.3 | |||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 19.7 | 25.3 | 11.7 | |||||||
cash-flows.row.operating-cash-flow | 0 | 5.1 | 0.6 | 0.3 | |||||||
cash-flows.row.capital-expenditure | 0 | -4.9 | -5.6 | -6.3 | |||||||
cash-flows.row.free-cash-flow | 0 | 0.2 | -5 | -6 |
Gelir Tablosu Satırı
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 19.5 | 13.9 | 12.7 | |||||||
income-statement-row.row.cost-of-revenue | 0 | 2.8 | 3.2 | 3.2 | |||||||
income-statement-row.row.gross-profit | 0 | 16.7 | 10.7 | 9.5 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.operating-expenses | 0 | 16.2 | 10.2 | 9.7 | |||||||
income-statement-row.row.cost-and-expenses | 0 | 18.9 | 13.4 | 13 | |||||||
income-statement-row.row.interest-income | 0 | 0.1 | 0.1 | 0 | |||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0.1 | 0 | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0 | -0.1 | 0 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.total-operating-expenses | 0 | 0 | -0.1 | 0 | |||||||
income-statement-row.row.interest-expense | 0 | 0.1 | 0.1 | 0 | |||||||
income-statement-row.row.depreciation-and-amortization | 0 | 3 | 1.8 | 0.8 | |||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||
income-statement-row.row.operating-income | 0 | 0.6 | 0.6 | -0.7 | |||||||
income-statement-row.row.income-before-tax | 0 | 0.6 | 0.5 | -0.7 | |||||||
income-statement-row.row.income-tax-expense | 0 | -0.2 | -0.1 | -0.9 | |||||||
income-statement-row.row.net-income | 0 | 0.7 | 0.6 | 0.3 |
Sıkça Sorulan Sorular
Nedir Diaceutics PLC (DIUXF) toplam varlıklar?
Diaceutics PLC (DIUXF) toplam varlıklar 48256000.000 şeklindedir.
İşletmenin yıllık geliri nedir?
Yıllık gelir N/A'dur.
Firma kâr marjı nedir?
Firma kar marjı 0.796'dir.
Şirket serbest nakit akışı nedir?
Serbest nakit akışı -0.027'dur.
İşletme net kar marjı nedir?
Net kâr marjı -0.027'dir.
Firma toplam geliri nedir?
Toplam gelir -0.061'dur.
Nedir Diaceutics PLC (DIUXF) net kar (net gelir)?
Net kar (net gelir) 724000.000'dur.
Firmanın toplam borcu nedir?
Toplam borç 1329000.000'dir.
Faaliyet giderleri rakamı nedir?
İşletme giderleri 16166000.000'dır.
Şirket nakit rakamı nedir?
İşletme içi nakit 0.000'tir.